To test the hypothesis that melanoma brain metastases harbor a distinct alteration profile compared with extracranial melanoma, we evaluated clinical and molecular features within our cohort of 94 patients (70 men [74%] and 24 women [26%]) with resected melanoma brain metastasis and targeted BRAF alteration assessment (Table). The gene discussed is BRAF; the disease is melanoma.